The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Share News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 215.00
Bid: 210.00
Ask: 220.00
Change: 17.50 (8.86%)
Spread: 10.00 (4.762%)
Open: 192.50
High: 238.00
Low: 213.00
Prev. Close: 197.50
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Beowulf raises funds for Kallak iron ore project

Mon, 04th Mar 2024 19:59

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

----------

Beowulf Mining PLC - London-based mining company with projects in Sweden, Finland and Kosovo - Announces terms of previously announced fundraise. Says rights issue of Swedish depository receipts will raise up to GBP6.3 million, while a retail offer of ordinary shares in the UK will raise around GBP1.6 million. Notes the SDRs will be offered at SEK0.08 each and the shares at 0.61 pence each. Adds the SDRs will also be offered for subscription, without preferential rights, to institutional investors, other professional investors and the general public in Sweden. Beowulf says it has has received underwriting commitments for the rights issue for around 60% of the total. Explains proceeds will be used mainly to finance the continued development of the Kallak iron ore project in northern Sweden, including completion of the ongoing pre-feasibility study and environmental studies. Funds will also repay amounts advanced under the bridge loan financing arrangements, and corporate costs.

----------

Kefi Gold & Copper PLC - exploration and development company focused on gold and copper projects in the Arabian-Nubian Shield - Plans to raise GBP4.5 million placing at 0.6 pence per share. Further, issues 83.3 million shares to cover accrued fees to certain directors and advisers. In addition, launches retail offer at the same issue price. Explains funds will underpin the launch of the Tulu Kapi Gold project by mid-2024.

----------

LungLife AI Inc - California-based developer of clinical diagnostic solutions for early lung cancer detection - Plans to raise around GBP1.8 million via a GBP1.56 million placing at 35 pence each and a GBP250,000 subscription at the same price. Explains net proceeds, along with existing cash resources, are expected to be utilised to establish the commercial proof of concept of the company's LungLB test. Notes funding is expected to provide the company with a cash runway to early April 2025.

----------

RC365 Holding PLC - London-based company focusing on payment gateway solutions and IT support services - Enters into an unsecured convertible loan note with Mill End Capital Ltd for up to GBP4 million. Says net proceeds of the unsecured loan will be used for the continuing development of existing operations with a particular focus on expanding operations in Malaysia, Japan and the UK. States the first tranche of the CLN comprises GBP600,000, the second tranche a further GBP1.4 million. Any further tranche shall be at the written request of RC365 and discretion of the lender, but will not exceed GBP4 million, RC365 says.

----------

Faron Pharmaceuticals Ltd - Turku-Finland-based clinical-stage biopharmaceutical company - Announces binding commitments worth GBP3.2 million for convertible loans obtained from certain existing shareholders. Explains this allows it to make critical payments to third parties under agreed waivers with IPF. Says this secures its short-term financing needs until the end of March. Faron says talks continue to secure its short and longer-term financing needs, including first additional bridge financing of around EUR5 million. In addition to the short-term bridge financing, Faron intends to propose to the Annual General Meeting an authorization for a larger share issue. In total, Faron expects to need EUR35 million of financing to complete the enrolment of the phase 2 of the BEXMAB study and to obtain regulatory feedback from the US Food & Drug Administration. At February 19, notes cash and cash equivalents held by Faron totalled EUR4.3 million.

----------

Supernova Digital Assets PLC - looks to identify investment and business building opportunities in the Solana and crypto currency ecosystem - Plans return to shareholders. Intends to achieve this by purchasing its own shares through a tender offer. Further, raises GBP242,000 via placing at 0.1 pence per share.

----------

Celsius Resources Ltd - explorer focused on portfolio of copper-gold resources in the Philippines - Advises that trading will be halted on the Australian Securities Exchange effective from March 5 further to the company's request. Celsius says it requested the suspension ahead of an announcement in relation to its flagship Maalinao-Caigutan-Biyog copper-gold project and the issuance of project sensitive documents by the Philippine National Government. Says trading on the AIM market of the London Stock Exchange remains unaffected.

----------

Kibo Energy PLC - Galway, Ireland-based company with energy projects in Africa and the UK - Sells shares in its subsidiary Mast Energy Developments PLC worth GBP29,350. Notes proceeds will be used to pay down the balance balance on the bridge loan facility with RiverFort Global Opportunities PCC Ltd. Holds 33% stake in MED following the share sale.

----------

Braveheart Investment Group PLC - Dodworth, England-based investment company - Provides update on one of its investments, Paraytec Ltd. Notes Paraytec develops high performance specialist detectors for the analytical and life sciences instrumentation markets. In December, Braveheart sought a buyer for Paraytec, of which it owns 100%. But, notes it has been unable to secure an attractive offer and therefore decides to retain Paraytec within its portfolio.

----------

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
9 Mar 2020 10:26

Faron gets FDA tick from proposed design of next 'Traumakine' study

(Sharecast News) - Faron Pharmaceuticals announced on Monday that the US Food and Drug Administration (FDA) has accepted its proposed protocol design for the next 'Traumakine' study in acute respiratory distress syndrome (ARDS) patients, following its protocol submission in February.

Read more
5 Mar 2020 14:28

Faron Pharmaceuticals "Encouraged" After Latest Matins Trial Findings

Faron Pharmaceuticals "Encouraged" After Latest Matins Trial Findings

Read more
2 Mar 2020 12:04

Faron Pharmaceuticals Buys Rights For AOC3 Antagonist Platform

Faron Pharmaceuticals Buys Rights For AOC3 Antagonist Platform

Read more
2 Mar 2020 10:08

Faron Pharmaceuticals acquires rights to AOC3 inhibitors

(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals has acquired rights for the potential new use of AOC3 inhibitors covered by a recently filed patent application.

Read more
6 Feb 2020 14:17

Faron Pharmaceuticals Alters Traumakine Study After US FDA Feedback

Faron Pharmaceuticals Alters Traumakine Study After US FDA Feedback

Read more
27 Jan 2020 11:22

Faron Pharma To Test Clevegen In Patients With Ovarian Cancer

Faron Pharma To Test Clevegen In Patients With Ovarian Cancer

Read more
13 Jan 2020 11:54

Faron Pharma Gets Approval For Part II Trial Of Clevegen Drug

Faron Pharma Gets Approval For Part II Trial Of Clevegen Drug

Read more
30 Dec 2019 15:39

Faron Pharma requests arbitration over Traumakine manufacturing deal

(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced on Monday that, further to the update on 'Traumakine' drug substance manufacturing on 2 October, it has carried out a detailed investigation into the circumstances around manufacturing arrangements.

Read more
30 Dec 2019 10:56

Faron Pharma Files For Arbitration Amid Traumakine Deal Termination

Faron Pharma Files For Arbitration Amid Traumakine Deal Termination

Read more
11 Dec 2019 13:42

Faron Pharmaceuticals upbeat on new data from 'MATINS' study

(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals announced new data from 'MATINS'-trial patients on Wednesday, to be presented at the ESMO Immuno-Oncology Congress 2019 in Geneva.

Read more
11 Dec 2019 10:45

Faron Pharmaceuticals Pleased With Clevegen Clinical Trial Performance

Faron Pharmaceuticals Pleased With Clevegen Clinical Trial Performance

Read more
29 Nov 2019 10:23

Faron Pharmaceuticals Inks Share Liquidity Pact With Lago Kapital

Faron Pharmaceuticals Inks Share Liquidity Pact With Lago Kapital

Read more
28 Nov 2019 11:56

Faron Pharmaceuticals Says US Regulator Approves Clevegen Drug Status

Faron Pharmaceuticals Says US Regulator Approves Clevegen Drug Status

Read more
21 Nov 2019 12:56

Faron Pharmaceuticals Applies For Nasdaq First North Growth Listing

Faron Pharmaceuticals Applies For Nasdaq First North Growth Listing

Read more
8 Nov 2019 10:30

UK WINNERS & LOSERS SUMMARY: Games Workshop And Beazley Top FTSE 250

UK WINNERS & LOSERS SUMMARY: Games Workshop And Beazley Top FTSE 250

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.